With much of Moderna’s rise in this decade tied to its COVID-19 vaccine, the company has struggled in recent years to match ...

Moderna, Inc. (MRNA) on Wednesday announced that it will bring drug product manufacturing to its existing Moderna Technology ...

Massachusetts-based vaccine maker Moderna on Thursday announced plans to cut its workforce by approximately 10%. Moderna CEO Stéphane Bancel notified employees of the decision. His memo explained that ...

The new plant will allow the company to execute end-to-end clinical- and commercial-stage production of its mRNA medicines.

Moderna said on Wednesday it would now operate full end-to-end manufacturing for its mRNA medicines in the U.S., marking a ...

Moderna (MRNA) stock gains as the firm projects 10% growth for next year ahead of the consensus as it plans to conduct the Analyst Day event on Thursday. Read more here.

Stephane Bancel is stepping down as chief commercial officer of Moderna Inc., according to a person familiar with the matter. He will remain chief executive of the biotech company. Moderna president ...

Announces three-year business strategy and commercial growth drivers, targeting up to 10% revenue growth in 2026 Expects to expand seasonal vaccine franchise from three to up to six approved products ...

Moderna is currently in the middle of an aggressive cost-cutting campaign. In September last year, the company announced that ...

Moderna on Thursday said it plans to slash roughly 10% of its global workforce by the end of the year, as Covid shot sales continue to dwindle and the company grapples with uncertainty in the vaccine ...

New capabilities strengthen U.S. production, completing Moderna’s domestic end-to-end mRNA manufacturing network More than $140 million investment will create hundreds of highly skilled ...